We yu tink bɔt kansa tritmɛnt, kemotɛrapi kin kam na yu maynd wantɛm wantɛm, nɔto so? Wi no am as tritmɛnt we de go ɔlsay na di bɔdi, we de afɛkt di kansa sɛl dɛn ɛn di sɛl dɛn we gɛt wɛlbɔdi, ɛn i gɛt sɔm siriɔs sayd ɛfɛkt dɛn. Bɔt imajin se we de fɔ fɛn di rayt say we di kansa sɛl de, gi am wan mɛrɛsin, ɛn pwɛl di kansa we nɔ go ambɔg di wɛlbɔdi sɛl dɛn we de nia am. Na dat wi go tɔk bɔt tide. Dɛn kɔl dis Antibody-Drug Conjugates, ɔ ADC fɔ shɔt tɛm.
Fɔ tɔk am simpul wan, wetin na dis Antibodi-Drug Conjugate (ADC)?
ADC na nyu ɛn rili prɔmis teknɔlɔji na di wɔl fɔ mɛn kansa. Insay dis, wi kin yuz tu men tritmɛnt we dɛn kin jɔyn: Targeted Therapy ɛn Chemotherapy.
Tink bɔt am lɛk ‘gayd mishɔl’ . Mishɔl kin fɛn in target ɛn na am nɔmɔ. Semweso, ADC tɛrapi kin pik ɛn pwɛl kansa sɛl dɛn frɔm di bɔku bɔku sɛl dɛn na di bɔdi. Wetin kin apin pan dis na dat, dɛn kin tek wan rili pawaful kemotɛrapi drɔg sef wan na di kansa sɛl ɛn dɛn kin injɛkt am insay am nɔmɔ. Dis min se di ifɛkt we di kemotɛrapi drɔg gɛt pan wɛlbɔdi sɛl dɛn nɔ bɔku.
Ɔnkɔlɔjis dɛn kin yuz dis ADC tritmɛnt fɔ:
- If kansa kam bak .
- If ɔda tritmɛnt dɛn nɔ wok (refractory cancer) .
- If di kansa spre to ɔda pat dɛn na di bɔdi (metastasizes) .
ADC tritmɛnt nɔ kin mɛn kansa ɔltogɛda, bɔt risach dɔn sho se di wan dɛn we gɛt dis tritmɛnt kin gɛt lɔng chans fɔ liv .
Okay, so hau dis ‘majik bulet’ we dem kol ADC de wok?
Dis kin tan lɛk se i at fɔ ɔndastand smɔl, bɔt lɛ wi ɔndastand am wit wan simpul ɛgzampul. Imajin se dɛn dɔn kɛr wan pasɛl we dɛn ɔda na di Intanɛt go na yu os.
Dis ADC pakej gɛt tri men pat dɛn:
1. Monoklonal Antibodi: Dis na wi delivri ejen. Dis na spɛshal prɔtin we dɛn kin mek na di lɛb. i gεt di amazing abiliti fכ no wan spεshal mak na di sεf fכ di kεnsar sεl dεm (wi kכl dεn Tumor Antigens ). Jɔs lɛk aw ki kin fit insay lɔk, dis antibodi kin go to da mak de na di kansa sɛl ɛn stik to am. I nɔ de stik to ɛni ɔda wɛlbɔdi sɛl.
2. Spɛsifi k kemotɛrapi drɔg:Dis na di paket we dɛn de sɛn. Dɛn mɛrɛsin ya pawaful pas di kemotɛrapi we dɛn kin tek ɔltɛm. Bɔt if dɛn sɛn dis mɛrɛsin na di bɔdi nɔmɔ, i kin pwɛl di sɛl dɛn we gɛt wɛlbɔdi. Na dat mek wi kin sɛn am to di delivri ɛjɛn.
3. "Linker" protin: dis na di pat we lεk 'gכm' we de kכnekt di dεlivεri ejen εn di pasεl tכgeda. I gɛt tu wok dɛn we i de du. di fכs wan na fכ ol di pasεl (kimothεrapi dכg) tayt te di dεlivεri ejen (antibodi) fכn di kεnsar sεl. Di sɛkɔn ɛn impɔtant tin na fɔ fri di pasɛl ɛn sɛn am insay di kansa sɛl we i rich di rayt ples.
So na so dɛn tri ya de wok togɛda:
- we dεn injεkt di ADC dכg insay di bכdi, di dεlivεri ejen (antibodi) de travul כlsay na di bכdi εn de luk fכ kεnsar sεl dεm.
- We dɛn fɛn kansa sɛl, i kin go na in fes ɛn stik pan am.
- afta dat, di kεnsar sεl de pul dis ADC insay.
- We i dɔn go insay di sɛl, da linka de kin brok, ɛn di paket (di kemo drɔg) kin kɔmɔt.
- Dis pawaful mɛrɛsin de pwɛl di kansa sɛl dɛn we de insay dɛn.
Fɔ tɔk am simpul wan, dis tritmɛnt we dɛn kin yuz rili spɛshal bikɔs i kin tɔch ɛn gi di mɛrɛsin to di kansa sɛl dɛn nɔmɔ, ɛn i nɔ kin ambɔg di sɛl dɛn we gɛt wɛlbɔdi.
Us kayn kansa dɛn kin trit wit ADC?
Naw, dɛn nɔ de yuz ADC tritmɛnt fɔ ɔl kayn kansa. Bɔt dɛn dɔn gri fɔ dis tritmɛnt fɔ bɔku kayn kansa dɛn. I go mɔs bi se dis list go bɔku tumara bambay.
| Kansa kategori | Ɛgzampul dɛn |
|---|---|
| Blɔd Kansa dɛn |
|
| Tumɔs dɛn we gɛt kansa |
Bɔku ADC drɔgs dɛn we dɛn de yuz naw
Naw, i pas wan duzin ADC mɛrɛsin dɛn we di US FDA dɔn gri fɔ. Sɔm ɛgzampul dɛn na:
- Brentuximab vedotin (Adcetris®): Na wan pan di fɔs ADC dɛm we gɛt FDA aprɔval. Dɛn kin yuz am fɔ trit blɔd kansa lɛk Hodgkin lymphoma ɛn anaplastic big cell lymphoma.
- Trastuzumab emtansine (Kadcyla®): Dɛn kin yuz am fɔ trit HER2-positiv brɔst kansa we dɔn skata ɔlsay na di bɔdi.
- Sacituzumab govitecan (Trodelvy®): Na tritmɛnt fɔ in ɔpreshɔn, advans triplɛ-nɛgitiv brɔst kansa. Dɛn kin yuz am bak fɔ kansa we dɔn go bifo pan urinary tract.
Naw, di wan dɛn we de du risach de chɛk if dɛn kin yuz dɛn mɛrɛsin ya fɔ ɔda kayn kansa ɛn sik dɛn we nɔto kansa. I pas 100 klinik trial dɛn we dɛn de du ɔlsay na di wɔl.
Wetin na di men bɛnifit dɛn we ADC tritmɛnt gɛt?
Di big ɛn impɔtant bɛnifit fɔ dis tritmɛnt na dat i kin gi kemotɛrapi drɔgs dairekt to kansa sɛl dɛn we nɔ go ambɔg di wɛlbɔdi sɛl dɛn. Dis kin mek dɔktɔ dɛn ebul fɔ yuz kemotɛrapi mɛrɛsin dɛn we rili pawaful ɛn dɛn nɔ kin fred fɔ ambɔg di sɛl dɛn we gɛt wɛlbɔdi.
Insay tradishɔnal kemotɛrapi, dɛn kin gi di mɛrɛsin tru wan blɔd vesel ɔlsay na di bɔdi. Dɛn kɔl dis sistɛm kimotɛrapi. We di mɛrɛsin travul ɔlsay na di bɔdi dis we, i nɔ jɔs de pwɛl di kansa sɛl dɛn we de sheb kwik kwik wan, bɔt i de pwɛl di sɛl dɛn we gɛt wɛlbɔdi lɛk wi ia sɛl dɛn, di sɛl dɛn we de mɛn wund dɛn na wi mɔt, ɛn di sɛl dɛn we de mek blɔd. Dis na di men rizin fɔ di sayd ɛfɛkt dɛn we de bɔku.
Bɔt dis prɔblɛm nɔ kin bɔku wit ADC tritmɛnt. Na dat mek sɔm ɔnkɔlɔjis dɛn kin ivin yuz nem dɛn lɛk "magic bullet" ɛn "precision treatment" fɔ dis tritmɛnt.
Lɛk ɔl ɔda tin, ɛni bad bad tin de we kin apin to dis?
Yɛs. ADC tritmɛnt kin mek yu gɛt sayd ɛfɛkt. Bɔt bɔku tɛm dɛn tin ya nɔ kin bɔku pas di wan dɛn we dɛn kin yuz tradishɔnal kemotɛrapi. De sayd effekt wae kin apun kin difrɛn frɔm wan pɔrsin to ɔda pɔrsin. Dis kin dipen pan tin dɛm lɛk di kayn kansa wae yu gɛt, di stej wae de kansa de, ɛn yu ɔl wɛl bɔdi.
If yu de gɛt ADC tritmɛnt, yu mɛdikal tim go wach yu gud gud wan. If ɛni sayd ɛfɛkt kam, dɛn go wok fɔ trit am kwik.
| Kɔmɔn pɔsibul sayd ɛfɛkt dɛn |
|---|
|
| Ustɛm fɔ tɛl yu dɔktɔ |
If di sayd ɛfɛkt dɛn bad pas aw yu bin de tink, fɔ ɛgzampul, if yu gɛt nɔys ɛn vɔmit we yu nɔ ebul fɔ kɔntrol, tɛl yu dɔktɔ wantɛm wantɛm. |
Aw ADC tritmɛnt kin wok fayn?
In jɛnɛral, risach dɔn sho se di wan dɛn we gɛt ADC tritmɛnt de liv lɔng pas di wan dɛn we de gɛt tradishɔnal kemotɛrapi fɔ di sem kayn kansa. Bɔt di tin dɛn we kin apin kin difrɛn frɔm wan pɔsin to ɔda pɔsin. Bɔku tin dɛn de we kin afɛkt dis:
- Di kayn kansa: ADC tritmɛnt kin rili wok fɔ sɔm kayn kansa. Sɔntɛm i nɔ go wok fɔ ɔda pipul dɛn.
- Stej we kansa gɛt: Fɔ trit kansa we dɔn skata ɔlsay na di bɔdi na prɔblɛm ɔltɛm.
- Yu ɔl wɛl bɔdi: Dis tritmɛnt kin mek yu gɛt siriɔs sayd ɛfɛkt, so yu bɔdi nid fɔ ebul fɔ bia wit am. Yu dɔktɔ we de mɛn yu kansa go ɛksplen dis to yu gud gud wan bifo i gi yu dis tritmɛnt.
Di wɔd "op" rili valyu to pɔsin we de fɛt kansa. ADC tɛrapi na dis kayn nyu op. Dis tritmɛnt kin ɛp pipul dɛm wae nɔr dɔn du ɔda tritmɛnt ɛn wae dɛn kansa dɔn kam bak fɔ liv lɔng ɛn gɛt bɛtɛ kwaliti layf.
Mɛsej we dɛn kin kɛr go na os
- Antibodi-Drug Conjugates (ADCs) na wan advans tritmɛnt fɔ kansa we de jɔyn targeted therapy ɛn kemotherapy.
- Wetin kin apin pan dis na dat na di kansa sɛl dɛn nɔmɔ dɛn kin fɛn ɛn dɛn kin injɛkt wan pawaful kemo drɔg insay dɛn fɔ pwɛl dɛn. I tan lɛk ‘guided missile’.
- Dis kin mek di sɛl dɛn we gɛt wɛlbɔdi ɛn di sayd ɛfɛkt dɛn nɔ bɔku pas di tradishɔnal kemotɛrapi.
- Naw dɛn de yuz dis tritmɛnt fɔ sɔm kayn blɔd kansa ɛn sɔlid kansa lɛk brɔst, lɔng, ɛn sɛvikal.
- Yu dɔktɔ we de mɛn kansa go disayd if dis tritmɛnt fayn fɔ yu. Tɔk bɔt ɔl yu kwɛstyɔn dɛn ɛn tin dɛn we de mɔna yu wit am.











💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt